Compare PRAX & MORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRAX | MORN |
|---|---|---|
| Founded | 2015 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.8B |
| IPO Year | 2020 | 2004 |
| Metric | PRAX | MORN |
|---|---|---|
| Price | $337.29 | $167.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 2 |
| Target Price | ★ $572.13 | $256.50 |
| AVG Volume (30 Days) | 326.2K | ★ 473.0K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.07% |
| EPS Growth | N/A | ★ 3.38 |
| EPS | N/A | ★ 2.73 |
| Revenue | N/A | ★ $2,445,500,000.00 |
| Revenue This Year | N/A | $9.14 |
| Revenue Next Year | $7,758.26 | $7.23 |
| P/E Ratio | ★ N/A | $61.71 |
| Revenue Growth | N/A | ★ 7.49 |
| 52 Week Low | $34.89 | $149.08 |
| 52 Week High | $354.87 | $316.71 |
| Indicator | PRAX | MORN |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 41.16 |
| Support Level | $282.49 | $165.70 |
| Resistance Level | $353.83 | $190.99 |
| Average True Range (ATR) | 18.75 | 7.03 |
| MACD | -0.96 | -1.44 |
| Stochastic Oscillator | 69.67 | 3.96 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Morningstar Inc is a provider of independent investment research to financial advisers, asset managers, and investors. The company focuses its operations on two core sectors: data and research. It offers data on investments such as mutual funds, stocks, exchange-traded funds, closed-end funds, separate accounts, and variable annuities. Further, the company tracks real-time market data of equity, derivative, currency exchanges, and other investments. In its research operation, Morningstar offers analyst research on passive and active mutual funds, alternative funds, and college saving plans. Morningstar's majority of the revenue is generated in the United States of America.